Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | FBP1 | P09467 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14874539 | 1.00 | METAP2 (0.53) | METAP2MAPTRAB9ANPC1APP | |
| SCHEMBL11133083 | 0.89 | MAPT (0.61) | METAP2MAPTRAB9ANPC1APP | |
| SCHEMBL11133082 | 0.89 | MAPT (0.61) | METAP2MAPTRAB9ANPC1APP | |
| SCHEMBL12918717 | 0.79 | KDM4E (0.67) | MAPTRAB9ANPC1SMN1; SMN2PTGS2 | |
| SCHEMBL31385202 | 0.78 | METAP2 (0.50) | METAP2MAPTRAB9ANPC1APP | |
| SCHEMBL8956458 | 0.78 | METAP2 (0.50) | METAP2MAPTRAB9ANPC1APP | |
| SCHEMBL9003171 | 0.77 | HPGD (0.59) | MAPTRAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL13863980 | 0.77 | KDM4E (0.51) | METAP2MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL458177 | 0.76 | APP (0.78) | MAPTRAB9ANPC1APPSMN1; SMN2 | |
| SCHEMBL458178 | 0.76 | APP (0.78) | MAPTRAB9ANPC1APPSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2583965-B1 | HETEROCYCLIC RING COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-25 | — | — | EP | disclosed |
| US-8937055-B2 | Heterocyclic ring compound having muscle cell or adipocyte differentiation regulating action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20130296276-A2 | HETEROCYCLIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130116214-A1 | HETEROCYCLIC RING COMPOUND | UJIKAWA OSAMU (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-2583965-A1 | HETEROCYCLIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2013-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116214-A1 | HETEROCYCLIC RING COMPOUND | FABP4, CPT1B, GPR119 | METAP2 3426/4885MAPT 4679/4885RAB9A 2276/4885 |
| US-20130296276-A2 | HETEROCYCLIC RING COMPOUND | FABP4, CPT1B, GPR119 | METAP2 3426/4885MAPT 4679/4885RAB9A 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.